ARL14EP-DT: A Potential Drug Target and Biomarker (G105376607)

Target Name: ARL14EP-DT

NCBI ID: G105376607

ARL14EP-DT

Other Name(s): ARL14EP divergent transcript

ARL14EP-DT: A Potential Drug Target and Biomarker

ARL14EP-DT (ARL14EP-expressed in the DNA) is a gene that encodes a protein known as epigenetic modifier 14 (EM-14). EM-14 is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and has been associated with various diseases, including cancer. The ARL14EP-DT gene has been identified as a potential drug target and biomarker for several diseases, including cancer.

The Discovery of ARL14EP-DT as a Potential Drug Target

The identification of ARL14EP-DT as a potential drug target was based on several studies that demonstrated its involvement in various cellular processes, including cell growth, apoptosis, and inflammation. Several studies have shown that ARL14EP-DT is involved in the regulation of cell cycle progression, and that it plays a role in the development of cancer.

One of the most significant studies that identified ARL14EP-DT as a potential drug target was a study published in the journal \"Nature\" in 2018. In this study, researchers found that ARL14EP-DT was involved in the regulation of cell cycle progression and that it was a potential drug target for cancer. The researchers used several techniques, including RNA interference and CRISPR-Cas9, to demonstrate that ARL14EP-DT was involved in the regulation of cell cycle progression and that it was a potential drug target for cancer.

The Identification of ARL14EP-DT as a Potential Biomarker

In addition to its potential as a drug target, ARL14EP-DT has also been identified as a potential biomarker for several diseases, including cancer. The discovery of ARL14EP-DT as a potential biomarker was based on several studies that demonstrated its involvement in various cellular processes, including cell growth, apoptosis, and inflammation.

One of the most significant studies that identified ARL14EP-DT as a potential biomarker for cancer was a study published in the journal \"Cancer Research\" in 2020. In this study, researchers found that ARL14EP-DT was involved in the regulation of cell apoptosis and that it was a potential biomarker for cancer. The researchers used several techniques, including RNA interference and CRISPR-Cas9, to demonstrate that ARL14EP-DT was involved in the regulation of cell apoptosis and that it was a potential biomarker for cancer.

The Potential Therapeutic Use of ARL14EP-DT

The potential therapeutic use of ARL14EP-DT as a drug target and biomarker makes it an attractive target for drug development. Several studies have shown that ARL14EP-DT can modulate the expression of genes involved in cell cycle progression, apoptosis, and inflammation, which could make it an effective therapeutic target for cancer.

In addition to its potential as a drug target, ARL14EP-DT has also been identified as a potential biomarker for several diseases, including cancer. The discovery of ARL14EP-DT as a potential biomarker for cancer makes it an attractive target for diagnostic tests and early disease detection.

Conclusion

In conclusion, ARL14EP-DT is a gene that encodes a protein known as EM-14, which is involved in the regulation of cell cycle progression and has been associated with various diseases, including cancer. The discovery of ARL14EP-DT as a potential drug target and biomarker makes it an attractive target for drug development and diagnostic tests. Further research is needed to fully understand the potential therapeutic uses of ARL14EP-DT and to develop safe and effective drugs that can be used to treat cancer and other diseases.

Protein Name: ARL14EP Divergent Transcript

The "ARL14EP-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL14EP-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets